Research
Hormonal
Lower birth weight is inversely associated with central (abdominal) obesity and metabolic syndrome risk after adjusting for attained adult BMI, creating a 'small baby, high BMI' phenotype with elevated cardiovascular risk.
If you were born small but became overweight as an adult, your risk for heart disease and diabetes is significantly higher than someone who was born larger and became overweight. Focus on preventing childhood obesity and managing abdominal fat, as this specific combination is a major driver of metabolic syndrome.
GoodQualifiesHIGH confidence
Lower birth weight seems to be associated with later risk for central obesity... The combination of lower birth weight and higher attained BMI is most strongly associated with later disease risk.
Why this rating
Supported by multiple studies showing inverse associations with central obesity measures, though mechanisms are less fully elucidated than for high birth weight.
Source
Fetal Origins of Obesity
Emily Oken et al. · Obesity Research · 2003
DOI 10.1038/oby.2003.69
narrative_reviewCited 902×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Prevention of obesity starting in childhood is critical and can have lifelong, perhaps multigenerational, impact, as fetal origins of obesity suggest that early life interventions are necessary to break the cycle of obesity and metabolic disease.Strong
- Higher birth weight is directly associated with higher attained Body Mass Index (BMI) in later life, indicating that fetal growth patterns program long-term adiposity risk.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →